News | Jacobio Pharma

34 press releases in total

2021

Oct 15, 2021

Jacobio Receives IND Approval for CD73 mAb JAB-BX102 from FDA

[More]
Sep 1, 2021

Jacobio Pharmaceuticals Announces 2021 Interim Results

[More]
Aug 31, 2021

Jacobio Announces Strategic Investment in Hebecell to Further Develop iPSC-NK Cell Therapy

[More]
Aug 3, 2021

Jacobio Announces First Patient Dosed in Phase I/II Clinical Trial of KRAS G12C Inhibitor for Solid Tumour

[More]
Jun 18, 2021

Jacobio Announces First Two Patients Dosed in SHP2 Combination Study, Triggering US$20 Million Milestone Payment

[More]
May 3, 2021

Jacobio Announces FDA Approves IND Application to Develop KRAS G12C Inhibitor

[More]
Mar 29, 2021

Jacobio Pharma Announces CNY486 Million Revenue for 2020 Annual Results

[More]
Feb 26, 2021

Jacobio has been Selected as Constituent Stock of Hang Seng Composite Index

[More]

2020

Dec 1, 2020

Jacobio Announces First Patient Enrolled in Phase I Clinical Trial of BET Inhibitor JAB-8263

[More]
Jun 1, 2020

AbbVie pens cancer pact with U.S.-China biotech Jacobio

2019

Oct 10, 2019

Jacobio Receives IND Approval for SHP2 Inhibitor JAB-3312 from China CDE

[More]
Sep 16, 2019

Jacobio Enrolled First Patient in a Clinical Study of JAB-3312 in U.S.

[More]
Jul 9, 2019

Jacobio Receives IND Approval for SHP2 Inhibitor JAB-3312 from U.S. FDA

[More]
Jun 19, 2019

Jacobio's Innovative Drug Awarded Orphan Drug Designation for the Treatment of Esophageal Cancer by US FDA

[More]

Pages